Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 6, 2021 | Series B | $188M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
China Life Healthcare Fund | — | Series B |